Lantus

On Thursday, drugmaker Sanofi announced that it is joining Eli Lily and Novo Nordisk in reducing the price of insulin. The three companies, which dominate the global insulin market, were recently sued by the state of California, alleging they illegally drive up the cost of the drug.

“It seemed like only a matter of time before Sanofi also made changes,” said Stacie Dusetzina, a health policy professor at Vanderbilt University Medical Center. “You don’t want to be a standout.”

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the United States, by 78% and establishing a $35 monthly cap for those with private insurance, effective January 1, 2024, according to a statement. Uninsured Americans are eligible for Sanofi’s savings program, which enables them to buy one or multiple insulins for a 30-day supply for $35. Another offer allows the uninsured to buy the Soliqua injection for as little as $99 per box of pens.

 

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.